1. Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

2. Influenza Is a Serious Public Health Burden 2017-2018 Flu Season Was Unusually Severe

3. Vaccination Rates for Influenza Among Adults Decreased in 2017-2018

4. Influenza Antiviral Drugs Are an Important Adjunct to Vaccination

5. Commercially Available Antiviral Agents for Treatment and Prevention of Influenza in the United States

6. Neuraminidase Inhibitors Mechanism of Action

7. Oseltamivir

8. Oseltamivir Safety

9. Zanamivir

10. Peramivir

11. Viral Resistance to Neuraminidase Inhibitors: How Big a Problem?

12. Novel Antiviral Influenza Therapy: Baloxavir

13. Phase 3 Study of Baloxavir for Uncomplicated Influenza in Adults and Adolescents

14. Phase 3 Study of Baloxavir Efficacy

15. Phase 3 Study of Baloxavir Change in Influenza Infectious Viral Load

16. Phase 3 Study of Baloxavir Adverse Events

17. Resistance to Baloxavir in the Phase 3 Trial

18. Emerging Influenza Antiviral Agents

19. Who Should Get Influenza Antiviral Therapy?

20. High-Risk Patients

21. Practical Considerations for Influenza Antiviral Therapy

22. Concluding Remarks

23. Concluding Remarks (cont)

24. Abbreviations